These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 32185027)

  • 21. Dexmethylphenidate hydrochloride in the treatment of attention deficit hyperactivity disorder.
    Liu F; Minami H; Silva RR
    Neuropsychiatr Dis Treat; 2006 Dec; 2(4):467-73. PubMed ID: 19412495
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Testing tic suppression: comparing the effects of dexmethylphenidate to no medication in children and adolescents with attention-deficit/hyperactivity disorder and Tourette's disorder.
    Lyon GJ; Samar SM; Conelea C; Trujillo MR; Lipinski CM; Bauer CC; Brandt BC; Kemp JJ; Lawrence ZE; Howard J; Castellanos FX; Woods D; Coffey BJ
    J Child Adolesc Psychopharmacol; 2010 Aug; 20(4):283-9. PubMed ID: 20807066
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Dexmethylphenidate.
    Keating GM; Figgitt DP
    Drugs; 2002; 62(13):1899-904; discussion 1905-8. PubMed ID: 12215063
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Real-World Data on: Attention Deficit Hyperactivity Disorder Medication Side Effects.
    Cascade E; Kalali AH; Wigal SB
    Psychiatry (Edgmont); 2010 Apr; 7(4):13-5. PubMed ID: 20508803
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pharmacological treatment patterns among patients with attention-deficit/hyperactivity disorder: retrospective claims-based analysis of a managed care population.
    Christensen L; Sasané R; Hodgkins P; Harley C; Tetali S
    Curr Med Res Opin; 2010 Apr; 26(4):977-89. PubMed ID: 20178404
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The Effectiveness and Tolerability of Central Nervous System Stimulants in School-Age Children with Attention-Deficit/Hyperactivity Disorder and Disruptive Mood Dysregulation Disorder Across Home and School.
    Baweja R; Belin PJ; Humphrey HH; Babocsai L; Pariseau ME; Waschbusch DA; Hoffman MT; Akinnusi OO; Haak JL; Pelham WE; Waxmonsky JG
    J Child Adolesc Psychopharmacol; 2016 Mar; 26(2):154-63. PubMed ID: 26771437
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Extended-release dexmethylphenidate 30 mg/d versus 20 mg/d: duration of attention, behavior, and performance benefits in children with attention-deficit/hyperactivity disorder.
    Silva RR; Brams M; McCague K; Pestreich L; Muniz R
    Clin Neuropharmacol; 2013; 36(4):117-21. PubMed ID: 23860345
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Treatment discontinuation with methylphenidate in adults with attention deficit hyperactivity disorder: a meta-analysis of randomized clinical trials.
    Castells X; Cunill R; Capellà D
    Eur J Clin Pharmacol; 2013 Mar; 69(3):347-56. PubMed ID: 22983311
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Analysis of Growth Velocity in Children with Attention-Deficit/Hyperactivity Disorder Treated for up to 12 Months with Serdexmethylphenidate/Dexmethylphenidate.
    Childress AC; Cutler AJ; Patel M; Oh C
    J Child Adolesc Psychopharmacol; 2023 May; 33(4):134-142. PubMed ID: 37204277
    [No Abstract]   [Full Text] [Related]  

  • 30. Considerations in the Care of Athletes With Attention Deficit Hyperactivity Disorder.
    Pujalte GGA; Maynard JR; Thurston MJ; Taylor WC; Chauhan M
    Clin J Sport Med; 2019 May; 29(3):245-256. PubMed ID: 29189334
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy and safety of dexmethylphenidate extended-release capsules in adults with attention-deficit/hyperactivity disorder.
    Spencer TJ; Adler LA; McGough JJ; Muniz R; Jiang H; Pestreich L;
    Biol Psychiatry; 2007 Jun; 61(12):1380-7. PubMed ID: 17137560
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Novel treatments for attention-deficit/hyperactivity disorder in children.
    Spencer TJ; Biederman J; Wilens TE; Faraone SV
    J Clin Psychiatry; 2002; 63 Suppl 12():16-22. PubMed ID: 12562057
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A randomized, double-blind study of 30 versus 20 mg dexmethylphenidate extended-release in children with attention-deficit/hyperactivity disorder: late-day symptom control.
    Brams M; Turnbow J; Pestreich L; Giblin J; Childress A; McCague K; Muniz R
    J Clin Psychopharmacol; 2012 Oct; 32(5):637-44. PubMed ID: 22926597
    [TBL] [Abstract][Full Text] [Related]  

  • 34. α2-Adrenergic Agonists or Stimulants for Preschool-Age Children With Attention-Deficit/Hyperactivity Disorder.
    Harstad E; Shults J; Barbaresi W; Bax A; Cacia J; Deavenport-Saman A; Friedman S; LaRosa A; Loe IM; Mittal S; Tulio S; Vanderbilt D; Blum NJ
    JAMA; 2021 May; 325(20):2067-2075. PubMed ID: 33946100
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A double-blind, placebo-controlled withdrawal trial of dexmethylphenidate hydrochloride in children with attention deficit hyperactivity disorder.
    Arnold LE; Lindsay RL; Conners CK; Wigal SB; Levine AJ; Johnson DE; West SA; Sangal RB; Bohan TP; Zeldis JB
    J Child Adolesc Psychopharmacol; 2004; 14(4):542-54. PubMed ID: 15662146
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparative efficacy and tolerability of pharmacological interventions for attention-deficit/hyperactivity disorder in children, adolescents and adults: protocol for a systematic review and network meta-analysis.
    Cortese S; Adamo N; Mohr-Jensen C; Hayes AJ; Bhatti S; Carucci S; Del Giovane C; Atkinson LZ; Banaschewski T; Simonoff E; Zuddas A; Barbui C; Purgato M; Steinhausen HC; Shokraneh F; Xia J; Cipriani A; Coghill D;
    BMJ Open; 2017 Jan; 7(1):e013967. PubMed ID: 28073796
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effects of Dexmethylphenidate on Targeted and Non-Targeted Behaviours during Functional Analyses: A Brief Report.
    Torelli JN; Lambert JM; Francis RN; Picou CG; Mastel MA; O'Flaherty CA; Vandelaar EM
    Dev Neurorehabil; 2019 Nov; 22(8):565-568. PubMed ID: 30632865
    [No Abstract]   [Full Text] [Related]  

  • 38. Efficacy and duration of effect of extended-release dexmethylphenidate versus placebo in schoolchildren with attention-deficit/hyperactivity disorder.
    Silva RR; Muniz R; Pestreich L; Childress A; Brams M; Lopez FA; Wang J
    J Child Adolesc Psychopharmacol; 2006 Jun; 16(3):239-51. PubMed ID: 16768632
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pharmacotherapy of attention-deficit hyperactivity disorder in adolescents.
    Childress AC; Berry SA
    Drugs; 2012 Feb; 72(3):309-25. PubMed ID: 22316347
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Open-label study of dexmethylphenidate hydrochloride in children and adolescents with attention deficit hyperactivity disorder.
    Silva R; Tilker HA; Cecil JT; Kowalik S; Khetani V; Faleck H; Patin J
    J Child Adolesc Psychopharmacol; 2004; 14(4):555-63. PubMed ID: 15662147
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.